The tweet was deleted by the author.
But we saved everything 🙂.
Taysha Gene Therapies will announce its third quarter 2026 earnings and provide a corporate update next week.
The company is inviting stakeholders to visit its website for more information about the upcoming release and any additional details related to its business performance.
View post on X Loading...
In recent months, Taysha Gene Therapies has highlighted clinical progress on its TSHA-102 Rett syndrome program during a key neurology meeting, as reported here. The company also discussed advancements in its TSHA-102 gene therapy at the CNSAM event with the neurology community, according to a previous update. These updates follow Taysha’s ongoing communication with stakeholders about its product pipeline and clinical development.